Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

Abstract

In heavily pretreated patients with HER2-positive metastatic breast cancer, including those with brain metastases, adding tucatinib to trastuzumab and capecitabine resulted in better progression-free survival and overall survival outcomes than adding placebo; the risks of diarrhea and elevated aminotransferase levels were higher with tucatinib. (Funded by Seattle Genetics; HER2CLIMB ClinicalTrials.gov number, NCT02614794.).

Keywords

Affiliated Institutions

• Cliniques Universitaires Saint-Luc BE
• Palo Alto Institute US
• Sarah Cannon US
• Edinburgh Cancer Research GB
• University of Milan IT
• University of California, Los Angeles US
• University Health Network CA
• German Breast group DE
• Duke Cancer Institute
• Vall d'Hebron Hospital Universitari ES
• Paracelsus Medical University AT
• The University of Texas MD Anderson Cancer Center US
• Hospital do Desterro PT
• Piedmont Cancer Institute US
• Royal Marsden NHS Foundation Trust GB
• University of North Carolina at Chapel Hill US
• Princess Margaret Cancer Centre CA
• Winship Cancer Institute
• Centre Léon Bérard FR
• Eppendorf (Germany) DE
• Peter MacCallum Cancer Centre AU
• Vejle Sygehus DK
• Seagen (United States) US
• Hospital CUF Descobertas
• Lillebaelt Hospital DK
• University of Colorado Cancer Center US
• European Institute of Oncology IT
• UCLA Jonsson Comprehensive Cancer Center
• University of Colorado Denver US
• Dana-Farber Cancer Institute US
• UNC Lineberger Comprehensive Cancer Center
• Tennessee Oncology US
• Cancer Institute (WIA) IN
• Los Angeles Medical Center US
• Vanderbilt University Medical Center US
• Rambam Health Care Campus IL

Related Publications